A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse
clinical paper · 2002
LINK
SUMMARY
Peer-reviewed pharmacology review, identifiers confirmed directly on the PubMed record: Biochem Pharmacol 63(2):89-98, 2002, authors Linda P. Dwoskin and Peter A. Crooks, DOI 10.1016/s0006-2952(01)00899-1, PMID 11841781. Used in this case as the modern pharmacological source on lobeline, the principal alkaloid of Lobelia inflata: lobeline acts at neuronal nicotinic acetylcholine receptors and inhibits the vesicular monoamine transporter (VMAT2), a real, measurable pharmacological action distinct from Thomson's own claimed mechanism (clearing bodily 'obstructions' to restore natural heat). The paper situates lobeline's known effects (including emesis) within modern receptor pharmacology rather than Thomson's vitalist theory, and frames lobeline's current investigational status (as a candidate treatment for psychostimulant dependence) as unproven and preclinical/early-stage, not an established therapy.
NOTES
Dwoskin and Crooks (Biochemical Pharmacology, 2002; PMID 11841781, DOI 10.1016/s0006-2952(01)00899-1) is the modern pharmacology source used for the Lobelia inflata ingredient entity: lobeline’s actual, receptor-level mechanism (nicotinic receptor activity and VMAT2 inhibition), which explains its real emetic and autonomic effects without supporting Thomson’s own vitalist “obstruction”-clearing theory or his broader disease-curing claims.